Olmesartán/Hidroclorotiazida Aurovitas (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan/hydrochlorothiazide is used in the management of cardiovascular conditions that involve fluid retention and elevated vascular resistance.

• Hypertension: low‑blood pressure control in patients requiring combined ARB and diuretic therapy.
• Congestive heart failure: adjunctive treatment to reduce preload and afterload.
• Edema associated with renal or hepatic disease: promotes diuresis and lowers blood pressure.
• Diabetic nephropathy: helps protect renal function by controlling hypertension.

• Olmesartan medoxil is hydrolysed to olmesartan, which selectively blocks the binding of angiotensin II to the AT‑1 receptor on vascular smooth‑muscle and adrenal cells, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide acts on the distal convoluted tubule, inhibiting Na⁺/Cl⁻ reabsorption, increasing urinary sodium and water excretion, and thereby lowering plasma volume and blood pressure.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia or severe electrolyte imbalance
• Angio‑edema
• Liver function abnormalities
• Blood dyscrasias such as agranulocytosis

Patients should be evaluated for potential risks before initiating therapy and monitored regularly.

• Renal impairment: adjust dose and monitor kidney function.
• Hepatic disease: use with caution, monitor liver enzymes.
• Electrolyte balance: check serum potassium and sodium regularly.
• Pregnancy: contraindicated in the second and third trimesters; avoid unless clearly needed.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/hydrochlorothiazide may interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid)

• Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyperkalemia.
• Aliskiren (in diabetic patients): increased risk of renal dysfunction.
• NSAIDs (high‑dose or chronic use): may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Lithium: may increase serum lithium levels.
• Antidiabetic agents: enhanced hypoglycaemic effect.
• ACE inhibitors or other ARBs: additive risk of hypotension and renal impairment.
• Antacids containing aluminium or magnesium: may reduce absorption of olmesartan.